OKYO Pharma获得140万美元非稀释性资金，增持

2025-01-22 20:39

OKYO Pharma (NASDAQ:OKYO) Wednesday said that it has received $1.4 million in non-dilutive funding, sending shares up in early trade.
The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO’s lead program, OK-101 focused on treating NCP, a major unmet medical need.
“Securing $1.4 million in non-dilutive funding marks an important milestone for OKYO Pharma. This financial boost will significantly contribute to our mission of developing groundbreaking treatments for ophthalmic diseases,” commented Dr. Gary S. Jacob, CEO of OKYO Pharma (OKYO).
OKYO +10.58% premarket to $1.15.
Source: Press Release

More on OKYO Pharma